Nama's AI scorecard currently rates ResMed Strong Buy (8.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is RMD's P/E ratio?

ResMed trades at a trailing price-to-earnings ratio of 20.4.

When does RMD report earnings?

ResMed's next scheduled report is on Jan 28, 2027. Analysts expect EPS of $2.98.

What is the RMD price target?

The median analyst price target from 17 analysts is $270.00, with a range of $210.00 – $320.00.

Is RMD Shariah compliant?

Nama's AAOIFI-style screen reads ResMed as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Does RMD pay a dividend?

Yes — ResMed's dividend yield is 1.1%.

Nama Insights

ResMed (RMD)

Healthcare · Medical Instruments Supplies · NYSE

S&P 500

ResMed (RMD) is a Healthcare company in the Medical Instruments Supplies industry. It has a market capitalization of $33.10B, a trailing price-to-earnings ratio of 20.4 and a free-cash-flow yield of 3.7%. Over the most recent reported fiscal year, revenue grew 10.9% and free cash flow per share grew 129.8%. Nama's AI scorecard rates it Strong Buy, 8.7 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Strong Buy · 8.7/10

The top band of the Fundamental Verdict (8.6–10). As of Nov 7, 2026.

Momentum

Lagging · -9.5% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-19.9%

How far the last close sits under the highest price of the past five years.

Market cap	$33.10B
Trailing P/E	20.4
Price / book	5.2
Price / sales	5.8
FCF yield	3.7%
Dividend yield	1.1%
Gross margin	61.1%
Operating margin	33.8%
Net margin	26.9%
Revenue growth (YoY)	+10.9%
Revenue growth (3-yr annual)	—
EPS growth (YoY)	+19.8%
FCF/share growth (YoY)	+129.8%
Beta	0.8
Exchange	NYSE
Sector	Healthcare
Industry	Medical Instruments Supplies

RMD earnings

Next report: Jan 28, 2027 (Q2 2027, EPS estimate $2.98). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q1 2027	Oct 29, 2026	$2.91	$2.67	+9.0%	$1.41B
Q4 2026	Aug 6, 2026	$2.95	$2.89	+2.1%	$1.46B
Q3 2026	Apr 30, 2026	$2.86	$2.80	+2.1%	$1.43B
Q2 2026	Jan 29, 2026	$2.81	$2.72	+3.3%	$1.42B

RMD analyst price target

Median target $270.00 from 17 analysts, ranging $210.00 – $320.00.

Medical Instruments Supplies peers

Ticker	Company	Market cap	P/E
ISRG	Intuitive Surgical	$159.96B	41.8
BDX	Becton, Dickinson	$57.71B	16.1
MDLN	Medline	$52.17B	25.1
ALC	Alcon	$36.23B	23.0
WST	West Pharmaceutical Services	$27.85B	43.5
SOLV	Solventum	$15.38B	12.8
BAX	Baxter International	$13.34B	13.3
COO	Cooper Companies	$11.86B	13.5

Explore live RMD data on Nama Insights →

Recent Congressional trades

ResMed trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Thomas H Tuberville	Senate	Sell	$1,001 - $15,000	Aug 5, 2026
Alan Armstrong	Senate	Buy	$1,001 - $15,000	Jul 21, 2026
Kelly Louise Morrison	House	Sell	$1,001 - $15,000	Jun 18, 2025
Rob Bresnahan	House	Sell	$1,001 - $15,000	Feb 13, 2025
Thomas R Carper	Senate	Sell	$1,001 - $15,000	—
Thomas R Carper	Senate	Sell	$1,001 - $15,000	—
Thomas R Carper	Senate	Buy	$1,001 - $15,000	—

RMD FAQ

Is RMD a buy?: Nama's AI scorecard currently rates ResMed Strong Buy (8.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is RMD's P/E ratio?: ResMed trades at a trailing price-to-earnings ratio of 20.4.
When does RMD report earnings?: ResMed's next scheduled report is on Jan 28, 2027. Analysts expect EPS of $2.98.
What is the RMD price target?: The median analyst price target from 17 analysts is $270.00, with a range of $210.00 – $320.00.
Is RMD Shariah compliant?: Nama's AAOIFI-style screen reads ResMed as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.
Does RMD pay a dividend?: Yes — ResMed's dividend yield is 1.1%.